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Objectives:Non-cardiovascular comorbidity is common in cardiovascular disease (CVD) populations but its inﬂu-
ence on chest pain (CP) and shortness of breath (SOB) symptom-speciﬁc physical limitations is unknown. We
wanted to test the a priori hypothesis that an unrelated comorbidity would inﬂuence symptom-speciﬁc physical
limitations and to investigate this impact in different severities of CVD.
Method and results: The studywas based on 5426 patients from ten family practices, organised into eight a priori
exclusive severity groups: (i) no CVD or osteoarthritis (OA) (reference), (ii) index hypertension, ischaemic heart
disease (IHD) and heart failure (HF) without OA, (iii) index OA without CVD and (iv) same CVD groups with
comorbid OA. The measure of CP physical limitations was Seattle Angina Questionnaire and for SOB physical
limitations was the Kansas City Cardiomyopathy Questionnaire. Adjusted baseline associations between the co-
horts and symptom-speciﬁc physical limitations were assessed using linear regression methods. In the study
population, 1443 (27%) reported CP and 2097 (39%) SOB. CP and SOB physical limitations increased with CVD
severity in the index and comorbid groups. Comparedwith the respective index CVD group, the CP physical lim-
itation scores for comorbid CVD groups with OA were lower by:−14.7 (95% CI−21.5, 7.8) for hypertension,
−5.5 (−10.4,−0.7) for IHD and−22.1 (−31.0,−6.7) for HF. For SOB physical limitations, comorbid scores
were lower by:−9.2 (−13.8,−4.6) for hypertension,−6.4 (−11.1,−1.8) for IHD and−8.8 (−19.3, 1.65)
for HF.
Conclusions: CP and SOB are common symptoms, and OA increases the CVD symptom-speciﬁc physical limita-
tions additively. Comorbidity interventions need to be developed for CVD speciﬁc health outcomes.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cardiovascular diseases (CVD) and osteoarthritis (OA) often co-
occur [1] and individually impact adversely on disease-speciﬁc symp-
toms and poor health [2,3]. Yet, their common co-occurrence suggests
that there might be shared causal links [4–6], as well as shared conse-
quences in relation to overall health [7,8]. Individual studies, for exam-
ple of CVD or OA, tend to focus on speciﬁc outcomes, which often use a
main symptom characteristic as a rationale for distinguishing from
broader limitations of disease and health. In ischaemic heart disease,
the symptom focus is localised to chest pain as a presenting feature of
angina [9], whilst in heart failure, the symptom focus is on shortness
of breath limitations [10]. Yet, pain is also a focus for osteoarthritis,arthritis; IHD, ischaemic heart
f breath; PL, physical limitation;
nd depression.
nit, Innovation Centre 2, Keele
: +44 1782 733768; fax: +44
).
nd Ltd. This is an open access article ubut localised to the joint [11], and shortness of breath is a feature of ac-
tivity limitation in the older population often associated with the
comorbid presence of osteoarthritis [12].
Evidence for shared symptomshas shown that generalised painmay
inﬂuence cardiovascular chest-speciﬁc pain [13] and obesity is a shared
factor for limitations of cardiovascular or osteoarthritis-related activi-
ty [14,15]. Other studies link interventions for understanding shared
consequences, such as the use of anti-inﬂammatory drugs in osteoar-
thritis in the management of patients with CVD [16]. Such in-direct ev-
idence on comorbid links raises the speciﬁc hypothesis, as to whether
and how comorbidity inﬂuences disease speciﬁc outcomes, but here
the evidence is limited.
The stage of a disease provides a mechanism for identifying disease
severity and possible outcomes. In HF, for example, the stage of disease
as recognized by increasing symptoms, has been associated with poor
quality of life, increased hospital admissions and mortality [17], and in
OA, the severity of disease has been associated with increasedmortality
risk [18]. CVD represents a biological spectrum of linked conditions,
from hypertension to end-stage HF and the individual diseases that de-
velop as CVD progresses can provide a notion of disease spectrumnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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limitations [19]. What is less well known is how individual diseases
within the CVD spectrum are inﬂuenced by the comorbid addition of
another chronic disease such as OA.
In CVD, the comorbid addition of another chronic disease may
impact on symptoms differently. ‘Biological interaction’ between two
diseases which is measured by comparing their combined effects on
a speciﬁc outcome with the sum of their independent effects is an
approach which has the potential for understanding about how one
disease impacts on another [23]. In this study we focus on biological in-
teraction, using an a priori epidemiological design, on disease-speciﬁc
outcomes which are an important consideration for clinical manage-
ment and treatment decisions.
In UK family practice, through 95% population registration, surveys
act as a population-level measure of symptoms and linked computer
clinical records act as an epidemiological measure of the development
of chronic disease [24]. We designed a cohort study, to test two speciﬁc
hypotheses: (i) increasing CVD severity and comorbid OA is associated
with increasing chest pain and shortness of breath physical limitations
and (ii) CVD and OA comorbidity increase symptom speciﬁc physical
limitations additively when compared to index groups.
2. Methods
2.1. Study population
Patients aged 40 years and over were recruited from 10 family practices in England,
which routinely record morbidity in computer consultations using standard diagnostic
and drug classiﬁcations. As a result of national pay-for-performance policies, high quality
computer disease registers particularly cardiovascular diseases have become an established
part of routine clinical practice [25].
2.2. Study design
The Comorbidity Cohort (2C) study was designed to investigate the interaction
between CVD andOA, using clinical-survey linkagemethods [26]. This studyhad a denom-
inator population registered with ten family practices, which links recorded clinical data
for speciﬁed CVD cohorts over a 5 year period to investigate healthcare outcomes and a
sub-cohort who took part in a survey to provide linkagewith patient reported health out-
comes. In this study, the 2C survey population was used to investigate the association be-
tween CVD and OA comorbidity in relation to CVD-speciﬁc symptoms, which were
measured using a postal questionnaire to obtain information on general health, pain and
speciﬁc measures of CVD. Ethical approval for the 2C study was granted by a Research
Ethics Committee (reference number: 09/H1017/40).
2.3. Study groups
Thestudygroupswere sampled from family practice computerised clinical records cov-
ering a three year time-period (November 2006–January 2010). In UK family practice, Read
codes [27] as a standard classiﬁcation are used to classify the morbidity of patients when
they present in consultation or when clinical data is coded, and CVD registers based on
these Read codes were identiﬁed in the three years before the baseline survey. In the
same3-year timeperiod before thebaseline survey, patientswithOAdiagnosis in their clin-
ical records were also identiﬁed. Using the presence or absence of CVD or OA diagnosis, a
total of 8 exclusive groupswere constructed: (i) a random reference group of patientswith-
out CVD or OA, (ii) three index CVD groups without OA (hypertension, IHD, HF), (iii) a ran-
dom index OA group without CVD, and (iv) three CVD groups with comorbid OA.
2.4. Study deﬁnitions
Three CVD deﬁnitions were chosen to reﬂect a spectrum of population severity [19].
Exclusive a priori ordering of CVD categories ranged in ‘severity’ from hypertension
(least severe) (Read and daughter codes beginning with G20) to IHD (Read and daughter
codes beginning with G3) to HF (most severe) (Read and daughter codes beginning with
G58 and heart failure codes related to NYHA classiﬁcation). Therefore, if a patient had a
record for more than one of the three CVD conditions they were placed into the most
‘severe’ group, for example, a patient who had a record for hypertension and HF over
the three year time-period would be placed in the HF group.
The OA deﬁnition was based on any coded clinical data, and included either diagnostic
labels for any OA-related joint problemor radiographic-related diagnosis (Read and daugh-
ter codes beginningwith N05 and codes related to OA joint replacement 7 K2 or 7 K3). Pre-
vious research also shows that the experience of osteoarthritis, which is usually presented
as a local joint problem, is in fact commonly associated with multiple pain sites [28]. This
approach to deﬁne three CVD groups for population severity and a single broader deﬁnition
of OA enabled the hypothesis testing of speciﬁc comorbid groups, without overcomplicating the design further with sub-groups of OA. Our previous work and other evi-
dence support the use of clinical records to measure both CVD population severity and
OA [19].2.5. Self-reported measurements
The Seattle Angina Questionnaire (SAQ) and the Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ) were used as symptom measures of chest pain (CP) and shortness of
breath (SOB) status respectively [29,30], and are widely used validated instruments in-
cluding for use in the UK population. The SAQ and KCCQ questionnaires were used in fam-
ily practice population samples, so a minor adaptation to the questionnaires was made to
focus on the symptom of chest pain or shortness of breath as experienced by wider
populations as opposed to the use of the clinical term such as ‘angina’ or ‘heart failure’
[31,32]. The SAQ has 3 sub-component scores and KCCQ has 5 sub-component scores
and in this analysis, survey participants were included if they had completed all the com-
ponents within each questionnaire. The physical limitation (PL) summary score, which is
the component shared by both questionnaires was used as a comparable measure of
symptom-based limitation. In addition, studydata available included age, gender, depriva-
tion, bodymass index (BMI), smoking status, alcohol, and hospital anxiety and depression
(HAD) questionnaire on psychological status [33]. The Index of Multiple Deprivation
(IMD) uses the individual patient postcode to indicate deprivation, and is a weighted
score relating to income; employment; health; education, skills and training; barriers to
housing, and access to local services; crime; and living environment [34].2.6. Statistical analysis
Study groupswere categorised by age, gender, deprivation, BMI, smoking and alcohol
status. Age was categorised into ﬁve groups and IMD score into four quartiles, with quar-
tile 1 (least deprived) to quartile 4 (most deprived). Smoking was categorised into three
groups (never, ex-smoker, smoker) and alcohol into six groups (never, special occasions,
monthly, weekly (1–2), weekly (3–4), daily). The physical limitation score, generated
from the SAQ and KCCQ was used as the primary ‘outcome’ measure in this analysis,
with a high score indicating low physical limitations and a low score indicating higher
physical limitations.
There were four stages to the analyses. First, symptoms and related mean physical lim-
itations are presented by age bands, gender, deprivation quartiles, BMI, smoking and alcohol.
Second, for each study group, themean physical limitation score with 95% conﬁdence inter-
valswas assessed. The associations between the index and comorbid study groups and phys-
ical limitations compared with the reference group were estimated using linear regression
methods, and expressed as the difference in physical limitation scores. Age, BMI, IMD,
smoking and alcohol were included as continuous variables in the linear regression models.
These analyses are presented as unadjusted values with 95% CI, then adjusted ﬁrst for age,
gender, deprivation, smoking and alcohol status, and ﬁnally adjusted in addition by BMI.
Separately we also adjusted for the psychological status as measured by the HAD scale as a
continuous variable (see Supplementary Table 1). Of total participants 7% were missing
data on BMI. All other variablesweremissing b5% of values. For BMIwe did not exclude sub-
jects with missing data but created a ‘dummy variable’ for the missing values. Third, we es-
timatedhow the observed associations betweenCVDandOA comorbid study groups andPLs
differed from the expected estimates for the comorbid groups compared to the reference
group.We calculated the observed estimates for the index and comorbid groups in linear re-
gression, and then calculated the expected ﬁgures by adding the estimates for the index CVD
and index OA groups. The difference between the observed and expected estimates for the
CVD comorbid groups in this additive approachwould allow the assessment of the potential
interaction between CVD and OA. Finally, we compared each comorbid group directly with
the respective index group, to assess the signiﬁcance of the OA impact on symptom-
speciﬁc physical limitation, and each comparison was adjusted for age, gender, deprivation,
alcohol, smoking and BMI. We used Stata version 12 to conduct all analyses.3. Results
3.1. CVD symptoms and PL in the study population
Of the 5426 study population, 1443 (27%) reported chest pain and
2098 (39%) shortness of breath symptom. Of the population with either
symptom, 395 (16%) patients had chest pain without SOB, 1049 (42%)
had SOB without chest pain, and 1048 (42%) had both symptoms.
Chest pain and shortness of breath symptoms and limitations
increased in prevalence with age, higher deprivation and smoking and
decreased in all but the highest alcohol intake group. Symptom limitation
was higher in women, but chest pain symptom prevalence was lower
(Table 1). The highest prevalence estimates were in the obese group
(32% for chest pain, 50% for SOB) and smokers (30% chest pain and 44%
SOB). Both symptoms and physical limitations were highest in the
group who did not consume any alcohol (chest pain 32% and SOB 48%).
Table 1
CVD symptoms and physical limitations in the study population.
Study factors Total Chest paina Shortness of breatha
No. (%) Mean score (SD) No. (%) Mean score (SD)
Age
40–49 439 61 (13.9) 81.9 (22.6) 102 (23.2) 78.0 (24.4)
50–59 966 212 (21.9) 71.2 (28.9) 303 (31.4) 68.4 (27.9)
60–69 1611 400 (24.8) 63.5 (28.5) 554 (34.4) 58.1 (28.2)
70–79 1541 495 (32.1) 58.8 (27.8) 707 (45.9) 51.5 (26.9)
80 years and over 869 275 (31.6) 52.0 (27.8) 431 (49.6) 44.5 (27.9)
Gender
Men 2653 780 (29.4) 64.6 (28.8) 1029 (38.8) 58.8 (29.3)
Women 2773 663 (23.9) 58.1 (28.4) 1068 (38.5) 53.8 (28.1)
Deprivation status
Quartile 1 — least 1412 314 (22.2) 69.1 (25.9) 483 (34.2) 62.4 (26.5)
Quartile 2 1430 360 (25.2) 65.2 (28.4) 507 (35.5) 59.0 (28.0)
Quartile 3 1350 368 (27.3) 60.6 (29.3) 543 (40.2) 54.5 (29.7)
Quartile 4 — most 1207 392 (32.5) 53.4 (29.0) 548 (45.4) 50.0 (29.2)
Body mass index
Normal 1479 329 (22.2) 65.7 (27.6) 469 (31.7) 60.1 (29.0)
Underweight 63 17 (27.0) 47.3 (31.0) 22 (34.9) 46.3 (31.2)
Overweight 2094 529 (25.3) 65.1 (28.2) 748 (35.7) 60.4 (28.0)
Obese 1407 449 (31.9) 57.6 (29.8) 704 (50.0) 51.9 (28.4)
Unknown 383 119 (31.1) 52.4 (26.8) 154 (40.2) 45.8 (27.5)
Smoking
Never 2456 563 (22.9) 69.9 (28.9) 843 (34.3) 58.2 (28.5)
Ex-smoker 2357 698 (29.6) 63.6 (29.8) 988 (41.9) 54.7 (28.7)
Smoker 487 147 (30.2) 64.8 (31.3) 213 (43.7) 53.8 (30.3)
Alcohol
Never 865 280 (32.4) 56.6 (30.7) 413 (47.7) 46.9 (28.0)
Special occasions 1096 314 (28.6) 63.5 (29.7) 490 (44.7) 53.1 (28.9)
Monthly 539 134 (24.9) 70.2 (27.6) 189 (35.1) 57.2 (28.6)
Weekly (1–2) 1144 273 (23.9) 69.0 (28.4) 414 (36.2) 61.1 (28.0)
Weekly (3–4) 785 179 (22.9) 73.2 (28.8) 237 (30.3) 65.2 (27.9)
Daily 748 184 (24.6) 72.6 (28.0) 262 (35.0) 58.7 (27.8)
a Chest physical limitations from Seattle Angina Questionnaire and shortness of breath physical limitations from Kansas City Cardiomyopathy Questionnaire.
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The highest mean chest pain physical limitation score was in the
reference study group (80.5; SD 24.9), and the lowest score was in the
HF and OA comorbid group (29.7; 21.8) (Table 2). With the exception
of the index hypertension and OA groups and the comorbid IHD
group, all other groups had signiﬁcant associationswith symptom relat-
ed physical limitations compared to the reference group and these asso-
ciations increased with CVD severity. The mean differences in physical
limitation scores, adjusting for age, gender, deprivation, smoking,Table 2
Associations between study groups and chest pain physical limitations.
Study groupsa Chest pain PLb (n = 1443)
No. (%) Mean score (SD)
Reference n = 1165 128 (11.0) 80.5 (24.9)
Hypertension n = 720 123 (17.1) 72.3 (24.4)
Ischaemic Heart Disease n = 1196 614 (51.3) 60.9 (27.7)
Heart failure n = 149 70 (47.0) 47.8 (27.0)
Osteoarthritis (OA) n = 828 131 (15.8) 65.6 (28.1)
Hypertension and OA n = 1017 194 (19.1) 57.7 (29.6)
Ischaemic heart disease and OA n = 305 160 (52.5) 52.0 (29.1)
Heart failure and OA n = 46 23 (50) 29.7 (21.8)
a Based on computer clinical records in 3-years before baseline— reference groupwithout CV
heart failure), index OA group without CVD categories and comorbid (CVD and OA) groups.
b Chest pain physical limitation from Seattle Angina Questionnaire.
c Adjusted for age, gender, deprivation measured by Index of Multiple Deprivation, smoking
d Adjusted additionally for Body Mass Index.alcohol and BMI, for the index CVD groups were: 2.7 (95% CI −3.6,
9.1) for hypertension, −8.1 (−13.7, −2.5) for IHD and −17.5
(−26.9, −8.1) for HF. The mean difference in physical limitation
score for the index OA group was−5.6 (−12.7, 1.5).
Themean differences in the physical limitation score for the CVD and
OA comorbid groups compared to the reference group were larger than
for the index groups and showed a similar observed trend with increas-
ing CVD severity (Fig. 1). Adjusting for age, gender, deprivation, smoking,
alcohol and BMI, the differences in CVD comorbid estimates were:
−11.6 (95% CI−20.0,−3.2) for hypertension,−7.6 (−15.5, 0.3) forUnadjusted Adjustedc Adjustedd
Difference (95% CI) Difference (95% CI) Difference (95% CI)
0 0 0
−8.2 (−14.3,−2.0) −0.9 (−7.0, 5.2) 2.7 (−3.6, 9.1)
−19.5 (−24.7,−14.3) −11.9 (−17.4,−6.3) −8.1 (−13.7,−2.5)
−32.7 (−40.2,−25.2) −20.0 (−29.3,−10.8) −17.5 (−26.9,−8.1)
−14.9 (−21.4,−8.4) −8.5 (−15.4,−1.7) −5.6 (−12.7, 1.5)
−22.7 (−29.0,−16.5) −16.0 (−23.8,−8.2) −11.6 (−20.0,−3.2)
−28.5 (−34.9,−22.1) −11.0 (−18.7,−3.3) −7.6 (−15.5, 0.3)
−50.8 (−61.7,−39.8) −30.2 (−43.0,−17.5) −25.4 (−37.6,−13.1)
D or OA, index CVD groupswithoutOA (hypertension, ischaemic heart disease and chronic
and alcohol intake.
Reference group without CVD or osteoarthritis (OA), index CVD groups without OA (hypertension (BP), 
ischaemic heart disease (IHD) and chronic heart failure (HF)), index OA group without CVD categories and comorbid 
(CVD and OA) groups; chest pain physical limitation from Seattle Angina Questionnaire
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Chest Pain Physical Limitation
Fig. 1. Chest pain physical limitation score difference of the study groups compared to reference group. Reference groupwithout CVD or osteoarthritis (OA), index CVD groupswithout OA
(hypertension (BP), ischaemic heart disease (IHD) and chronic heart failure (HF)), index OA group without CVD categories and comorbid (CVD and OA) groups; chest pain physical lim-
itation from Seattle Angina Questionnaire.
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ished the strength of associations between the disease-deﬁned groups
and chest pain physical limitations compared to the reference group,
but the associations remained signiﬁcant in all CVD comorbid groups
except for the IHD and OA group.
3.3. Associations between study groups and shortness of breath physical
limitations
The respective mean shortness of breath physical limitation scores
were all lower than the respective chest pain PL scores. The highest
mean shortness of breath physical limitation score was in the reference
study group (75.4; SD 25.8), and the lowest score was in the HF and OA
comorbid group (27.5; 20.8) (Table 3). With the exception of the index
hypertension group, all other groups had signiﬁcant associations with
physical limitations compared to the reference group and these associ-
ations increased with CVD severity. The mean differences in physical
limitation score, adjusting for age, gender, deprivation, smoking, alcohol
and BMI, for the index CVD groups were:−0.6 (95% CI−5.4, 4.3) for
hypertension, −12.9 (−17.4, −8.4) for IHD and −22.3 (−29.1,
−15.6) for HF. The mean difference in physical limitation score for the
index OA group was−10.5 (−15.2,−5.9).
The mean differences in the shortness of breath physical limitation
score for the CVD/OA comorbid groups compared to the reference
group were larger than for the index groups and as with chest painTable 3
Associations between study groups and shortness of breath physical limitations.
Study groupsa Shortness of breath PLb (n = 2097)
No. (%) Mean score (SD)
Reference n = 1165 257 (22.1) 75.4 (25.8)
Hypertension n = 720 244 (33.9) 65.0 (27.3)
Ischaemic Heart Disease n = 1196 650 (54.3) 53.7 (27.8)
Heart failure n = 149 108 (72.5) 39.7 (27.3)
Osteoarthritis (OA) n = 828 247 (29.8) 59.1 (27.0)
Hypertension and OA n = 1017 381 (37.5) 52.5 (27.0)
Ischaemic Heart Disease and OA n = 305 176 (57.7) 44.0 (26.8)
Heart failure and OA n = 46 34 (73.9) 27.5 (25.9)
a Based on computer clinical records in 3-years before baseline— reference groupwithout CV
heart failure), index OA group without CVD categories and comorbid (CVD and OA) groups.
b Shortness of breast physical limitation from Kansas City Cardiomyopathy Questionnaire.
c Adjusted for age, gender, deprivation measured by Index of Multiple Deprivation, smoking
d Adjusted additionally for body mass index.physical limitations, increased with CVD severity (Fig. 2). The mean
differences for the CVD comorbid groups, adjusting for age, gender, dep-
rivation, smoking, alcohol and BMI, were:−11.6 (95% CI−16.9,−6.4)
for hypertension and OA,−16.8 (−22.9,−10.7) for IHD and OA and
−29.5 (−39.7, −19.3) for HF and OA. Adjustment for BMI again,
diminished the strength of associations between the study groups com-
pared to the reference group. Additional adjustment for psychological
status did not change the estimates for either symptom (Supplementary
Table 1).
3.4. Assessing interaction: expected and observed estimates
The expected estimates for the adjusted associations (age, gender,
deprivation, smoking, alcohol and BMI) between CVD and OA comorbid
groups and chest pain physical limitations were as follows: hyperten-
sion (2.7) and OA (−5.6) = −2.9, IHD (−8.1) and OA (−5.6) =
−13.7, and HF (−17.5) and OA (−5.6) =−23.1. The respective ob-
served estimates were: −11.6, −7.6 and −25.4, which means that
the associations between CVD and OA comorbidity with CP limitations
weremore than additive for hypertension andHF, but less than additive
for IHD (Fig. 3). The expected estimates for the adjusted associations
between CVD and OA comorbid groups and SOB physical limitations
were as follows: hypertension (−0.6) and OA (−10.5) = −11.1,
IHD (−12.9) and OA (−10.5) = −23.4, and HF (−22.3) and OA
(−10.5) = −32.8. The respective observed estimates were: −11.6,Unadjusted Adjustedc Adjustedd
Difference (95% CI) Difference (95% CI) Difference (95% CI)
0 0 0
−10.4 (−15.0,−5.8) −2.4 (−7.2,2.3) −0.6 (−5.4, 4.3)
−21.7 (−25.6,−17.7) −15.7 (−20.1,−11.2) −12.9 (−17.4,−8.4)
−35.7 (−41.6,−29.8) −22.9 (−29.7,−16.1) −22.3 (−29.1,−15.6)
−16.3 (−20.9,−11.7) −12.6 (−17.1,−8.0) −10.5 (−15.2,−5.9)
−22.9 (−27.1,−18.7) −14.6 (−19.6,−9.5) −11.6 (−16.9,−6.4)
−31.4 (−36.5,−26.4) −17.7 (−23.8,−11.8) −16.8 (−22.9,−10.7)
−47.8 (−57.1,−38.6) −31.7 (−41.8,−21.5) −29.5 (−39.7,−19.3)
D or OA, index CVD groupswithoutOA (hypertension, ischaemic heart disease and chronic
and alcohol intake.
Reference group without CVD or osteoarthritis (OA), index CVD groups without OA (hypertension(BP), 
ischaemic heart disease(IHD)and chronic heart failure(HF)), index OA group without CVD categories and comorbid 
(CVD and OA) groups; shortness of breath physical limitation from Kansas City Cardiomyopathy Questionnaire
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Fig. 2. Shortness of breath physical limitation score difference of the study groups compared to reference group. Reference group without CVD or osteoarthritis (OA), index CVD groups
without OA (hypertension (BP), ischaemic heart disease (IHD) and chronic heart failure (HF)), index OA group without CVD categories and comorbid (CVD and OA) groups; shortness of
breath physical limitation from Kansas City Cardiomyopathy Questionnaire.
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and OA comorbidity with SOB limitations were around additive for
hypertension and HF, but less than additive for IHD (Fig. 4).3.5. Associations between OA and symptom-speciﬁc limitations
The CVD comorbid groups were compared to the respective index
CVD groups, to assess the OA ‘effect’ on chest pain and SOB physical lim-
itations (Table 4). For all three CVD groups, there were still signiﬁcant
associations with chest pain physical limitations and for hypertension
and IHD groups with SOB physical limitations. After adjustment for
age, gender, deprivation, smoking, alcohol and BMI, the difference in
the chest pain physical limitation score was: −14.7 (95% CI −21.5,
−7.8) for hypertension, −5.5 (−10.4, −0.7) for IHD and −22.1
(−31.0,−6.7) for HF. The CVD comorbid differences for shortness of
breath physical limitation estimates were −9.2 (−13.8, −4.6) for
hypertension, −6.4 (−11.1, −1.8) for IHD and −8.8 (−19.3, 1.65)Index groups; hypertension (BP),ischaemic heart disease (IH
Expected chest pain physical limitation scoreswere derived
OA index groups, whichwere compared to the observed scor
limitation from Seattle Angina Questionnaire).
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4. Discussion
The ﬁndings provide the evidence for the two study hypotheses.
First, increasing CVD severity was associated with increased chest pain
and SOB physical limitations in the index and comorbid groups. Second,
OA comorbidity added to the symptom-speciﬁc physical limitations, ir-
respective of CVD severity. Additionally, we found that OA signiﬁcantly
inﬂuenced symptom speciﬁc physical limitations in all CVD severity
groups. These associations were not explained by age, gender, depriva-
tion, smoking, alcohol and BMI.
There was a dose–response relationship between increasing CVD
severity and chest pain or SOB physical limitations. The CVD comorbid
associations were mostly additive i.e. the combined ‘effect’ was the
sum of individual parts, but there were differences between the two
symptom limitations. In all CVD severity groups, the mean physicalD), heart failure (HF), osteoarthritis (OA)
 from the sum of the independent effects of the CVD and 
es (o) in the comorbid groups(chest pain physical 
Index OA
Index CVD
Comorbid cohorts (expected)
Comorbid cohorts (observed)
(o)
HF
HF/OA(e)
HF/OA(o)
ension (BP), ischaemic heart disease (IHD), heart failure (HF), osteoarthritis (OA) expected
he CVD and OA index groups, which were compared to the observed scores (o) in the co-
Index groups; hypertension (BP),ischaemic heart disease (IHD), heart failure (HF), osteoarthritis (OA)
Expected shortness of breath physical limitation scores(e) were derived from the sum of the independent effects of the CVD 
and OA index groups, which were compared to the observed scores (o) in the comorbid groups(shortness of breathphysical 
limitation from Kansas City Cardiomyopathy Questionnaire).
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scores (o) in the comorbid groups (shortness of breath physical limitation from Kansas City Cardiomyopathy Questionnaire).
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had a greater comorbid ‘effect’ on chest pain physical limitations than
SOB when the comorbid group was compared directly with the index
CVD group. This implies that the impact of comorbidity on physical lim-
itation depends on the symptoms experienced by patients and requires
careful consideration within disease management consultations.
This study shows uniquely that an unrelated chronic disease of OA
has an independent effect in different cardiovascular diseases and on
CVD-speciﬁc outcomes. Much of the current evidence has shown that
comorbidity is associated with poor overall health and healthcare out-
comes [35,36], but very few primary comorbidity studies have investi-
gated the associations with disease-speciﬁc common symptoms and
limitations. Whilst comorbidity may have been considered as an alter-
native explanation and adjustment in disease-speciﬁc outcomes, there
has been a lack of focus onwhat the potential combined ‘effects’ of com-
mon chronic diseases are on speciﬁc limitations. This approach is crucial
if one is to understandhownew interventions for improvinghealth out-
comes might be developed and whether they are targeted at the index
disease or the comorbidity. The clearest analogy here, where there is
a substantial evidence base, is the identiﬁcation and treatment of
co-morbid depression in chronic diseases, to improve disease-speciﬁc
outcomes [37].
The other key ﬁndings were that despite CVD severity, OA comor-
bidity was independently associated with symptom-speciﬁc physical
limitations. Previous research has shown that hypertension and IHD
are associated with relatively better health than HF [19]. So an expecta-
tion would have been that there was more scope for comorbidity to in-
ﬂuence limitations in these CVD groups, than in the most severe HFTable 4
Associations between CVD comorbid groups and symptom related physical limitations compar
Study groups Chest pain PL differenced
Unadjusted (95% CI) Adjustedb (95% CI) Adjuste
Index CVD groupa 0 0 0
Hypertension and OA n = 1017 −14.6 (−20.8,−8.3) −14.7 (−21.3,−8.1) −14.7 (
Ischaemic heart disease and OA
n = 305
−8.9 (−13.8,−4.1) −6.2 (−11.0,−1.4) −5.5 (−
Heart failure and OA n = 46 −18.1 (−30.4,−5.7) −17.5 (−30.1,−4.9) −18.5 (
a Respective index group: i.e. hypertension, ischaemic heart disease and heart failure.
b Adjusted for age, gender, deprivation measured by Index of Multiple Deprivation, smoking
c Adjusted additionally for body mass index.
d Chest pain physical limitation from Seattle Angina Questionnaire; shortness of breast physgroup. Yet, the results show otherwise and there does not appear to
be ﬂoor effects that are observed in severe HF. Also it has been postulat-
ed that people with severe disease may become accustomed to poor
health and reconﬁgure their personal conceptualisations of ill-health
and its impact [38]. This so-called ‘response shift’ canmean that the per-
ception of symptom limitations might reduce in the presence of more
severe disease and comorbidity but we found that in HF the association
with speciﬁc-limitations was greater with comorbid OA and not less
than what might have been expected. There was also the strong effect
of BMI on the CVD associations with symptom-speciﬁc physical limita-
tions. High BMI is associated with both CVD and OA [39] and separately
for lower functional ability [40]. BMI may provide one explanation for
themechanism between the association between CVD severity, comor-
bid OA and symptom-speciﬁc limitations.
The study design allowed the a priori assessment of the biological
interaction between two common and important chronic diseases.
This allowed us to characterise the combined ‘effects’ and magnitude
of two chronic diseases on outcomes. Using this design approach we
were able to identify that the observed estimates of CVD and comorbid
OA compared to the expected estimateswere greater for chest pain lim-
itations than SOB limitations. The increased inﬂuence of OA on chest
pain physical limitations for the different CVD groups was further sup-
ported by the comparison of the comorbid groups with their respective
index CVD groups. The physical limitation score differences when OA
was present were greater for chest pain than for shortness of breath.
Previous studies have identiﬁed variations in the statistical level, but
not magnitude, of interaction of combined diseases on overall physical
health [20–22]. The study ﬁndings show the magnitude of combineded to index groups.
Shortness of breath PL differenced
dc (95% CI) Unadjusted (95% CI) Adjustedb (95% CI) Adjustedc (95% CI)
0 0 0
−21.5,−7.8) −12.5 (−16.8,−8.1) −10.4 (−14.9,−5.9) −9.2 (−13.8,−4.6)
10.4,−0.7) −9.8 (−14.4,−5.2) −7.1 (−11.7,−2.5) −6.4 (−11.1,−1.8)
−31.0,−6.0) −12.1 (−22.6,−1.7) −8.9 (−19.1, 1.4) −8.8 (−19.3, 1.65)
and alcohol intake.
ical limitation from Kansas City Cardiomyopathy Questionnaire.
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symptoms. The clinical implications are that in CVD management the
severity or stage of disease is important in self-reporting of speciﬁc
symptoms, which are common in the population, but that effective
CVD-speciﬁc symptom management requires inclusion of comorbidity
such as OA.
The study design incorporated exclusive CVD groups constructed on
the basis of a priori hypothesis, in a large population-based setting.
Exclusive groupswere constructed using chronic disease cardiovascular
and osteoarthritis registers. As such the deﬁnitions for the CVD groups
were based on prevalent cases, but the hypothesis can still test whether
the comorbid addition to an index condition is associated with greater
symptom limitations. The design with the reference and index groups
provides the basis for assessing the comorbid chronic disease interac-
tion, and for the matching potentially of other comorbidity in the
study groups. The symptom and physical limitations were measured
using validated instruments, and the design provides the method for
applying the same instruments to non-index conditions. Whilst most
disease-speciﬁc instruments identify the key symptom or diagnosis in
the population of interest, the underlyingmeasure of physical limitation
is often the same. Both the CVD measures used in the study in terms of
thephysical limitationshad the samequestion and related it to common
symptoms (chest pain and SOB) which occur not only in the CVD popu-
lation, but also in the non-CVDpopulation. Participation selection issues
for this study have been previously reported and is in line with similar
large population survey studies [26,41], but the design still allows for
internal hypothesis testing.
5. Conclusions
In CVD severity populations, chest pain and SOB are common symp-
toms and the comorbid addition of OA inﬂuences the speciﬁc-symptom
limitations. Clinically it provides evidence that pairs of common chronic
disease combinations indicate worse health, the impact of comorbidity
remains across different disease severities and the combined effect on
health is often the sum of the independent effects even in the most se-
vere disease. The clinical implication iswhether such changes as a result
of comorbidity inﬂuence clinical presentation and clinical decisions.
This evidence highlights the importance of comorbidity for speciﬁc
symptoms and that novel interventions for comorbidity need to be
developed for both CVD speciﬁc health outcomes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2014.05.001.
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